ASX - Delayed Quote • AUD
Firebrick Pharma Limited (FRE.AX)
At close: April 24 at 3:46 PM GMT+10
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Peter Laurence Molloy BSc, FAICD, MBA | Founder, Executive Chairman & CEO | 351.3k | -- | 1954 |
| Dr. Stephen Francis Goodall MASc, MBA | Founder, COO & Executive Director | 290.56k | -- | -- |
| Mr. Kavi Bekarma B.Sc., C.A. | Chief Financial Officer | -- | -- | -- |
| Dr. Simon Tucker | Chief Scientific Officer | -- | -- | -- |
| Prof. Peter Friedland | Chief Medical Officer | -- | -- | -- |
| Dr. Monique Baldwin | Head of Regulatory Affairs | -- | -- | -- |
| Mr. Stephen Buckley | Company Secretary | -- | -- | -- |
Firebrick Pharma Limited
440 Collins Street
Level 10
Melbourne, VIC 3000
Australia
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
Description
Firebrick Pharma Limited engages in the development and partnering of broad-spectrum antimicrobial spray for the treatment of common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.
Corporate Governance
Firebrick Pharma Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
Recent Events Information Not Available
Upcoming Events
Upcoming Events Information Not Available